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Abstract: Vascular adhesion protein-1 (VAP-1) is a multifunction protein. While membrane-bound
VAP-1 is an adhesion protein, soluble VAP-1 catalyzes the deamination of primary amines through
its semicarbazide-sensitive amino oxidase (SSAO) activity. VAP-1 supports the transmigration of
leukocytes and increases oxidative stress. In chronic liver diseases, it plays a role in leukocyte
infiltration and fibrogenesis. Here, we measured VAP-1 plasma concentration and its SSAO activity
in 322 patients with chronic hepatitis C infection and evaluated the association of VAP-1 with fibrosis
stages. VAP-1 concentration strongly correlated with liver stiffness and was the second strongest
influencing variable after gamma-glutamytransferase (GGT) for liver stiffness in regression analysis.
The VAP-1 concentration increased with advancing fibrosis stages and the highest concentrations
were found in patients with cirrhosis. According to the receiver operating characteristic (ROC)
analysis, a VAP-1 cut-off value of 541 ng/mL predicted histologically confirmed cirrhosis (sensitivity
74%; specificity 72%). SSAO activity correlated only moderately with liver stiffness, showing a
relatively small increase in advanced fibrosis. To our knowledge, this is the first study on VAP-1 in
chronic hepatitis C infection showing its association with progressive fibrosis. In conclusion, VAP-1
plasma concentration, rather than its SSAO activity, may represent a non-invasive biomarker for
monitoring fibrogenesis in patients with chronic hepatitis C infection.
Keywords: VAP-1; vascular adhesion protein 1; SSAO activity; semicarbazide-sensitive amino oxidase;
chronic liver diseases; fibrosis; liver stiffness; Fibroscan; HCV
1. Introduction
Vascular adhesion protein-1 (VAP-1) is a 170 kDa sialoglycoprotein. It exists in soluble and
membrane-bound forms [1]. VAP-1 has an enzymatic domain that is responsible for its primary amine
oxidase activity, also referred to as the semicarbazide-sensitive amino oxidase (SSAO) activity [2].
It is involved in the conversion of exogenous and endogenous amines, for example benzylamine and
methylamine, into aldehydes by oxidative deamination, thereby releasing cytotoxic products such as
hydrogen peroxide and ammonia. These cytotoxic products lead to increased oxidative stress and the
formation of advanced glycation endproducts [3]. On the other hand, VAP-1 non-enzymatically triggers
inflammation via an adhesion domain by attracting and supporting the adhesion and transmigration
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of leukocytes from vessels into the inflamed sites [4,5]. VAP-1 is stored in intracellular vesicles and
is present on the membranes of the endothelial cells, muscle cells, adipocytes and hepatic sinusoidal
endothelium. Under physiological conditions, the highest amount of membrane-bound VAP-1 exists
on the endothelial cells of the lymph nodes [6]. In the soluble form, VAP-1 is present in the human
blood [1].
VAP-1 concentration and, partly its SSAO activity, are modified in various pathological conditions,
such as atherosclerosis [7], chronic kidney injury [8] and diabetes mellitus [9]. In chronic diseases with
leukocyte infiltration, a considerable amount of VAP-1 is detectable on the endothelial cell surface
of the affected tissue. In chronic liver diseases (CLDs), for example, VAP-1 is present on the hepatic
sinusoidal endothelium and hepatic stellate cells [5,10,11].
The serum VAP-1 concentration differs between various CLDs, for example, patients with alcoholic
liver diseases (ALDs) have higher VAP-1 concentrations when compared to those with primary
biliary cholangitis and primary sclerosing cholangitis [6]. Moreover, significantly increased VAP-1
concentrations were detected in non-alcoholic fatty liver disease (NAFLD) patients in comparison to a
matched metabolic syndrome group [5]. Notably, VAP-1 concentration allowed distinction between
non-alcoholic steatohepatitis (NASH) and simple steatosis. Like other CLDs, chronic hepatitis C (HCV)
infection also results in fibrosis that may lead to the cirrhosis of the liver. According to the World
Health Organization (WHO), there are an estimated 71 million chronic HCV infected people in the
world [12]. Despite the availability of novel direct acting antiviral therapies, HCV infection is still the
most common cause of cirrhosis worldwide [12].
Here, we studied the concentration and the activity of plasma VAP-1 in patients with chronic
HCV infection. We investigated the levels of VAP-1 and SSAO activity in different fibrosis stages,
which were assessed by transient elastography (Fibroscan®) as liver stiffness and liver biopsy in some
cases. We aimed to discern diagnostic patterns and to estimate the informative value of measuring
VAP-1 concentration and activity as markers for fibrosis severity.
2. Experimental Section
This study was conducted on a subgroup of a study cohort consisting of 899 patients with different
CLDs [13]. From this cohort, we selected 538 subjects suffering from chronic HCV infection. Depending
on the availability of frozen blood samples and clinical parameters, 322 patients were considered
eligible for our study (Supplemental Figure S1). All patients gave written informed consent. The study
was approved by the local ethical committee (approval number of Ärztekammer des Saarlandes,
Germany: 271/11).
The liver stiffness of all 322 patients was measured by transient elastography (Fibroscan®,
Echosens SA, Paris, France) [13] as a non-invasive measurement of liver stiffness. We divided the
patients according to the fibrosis stages using the cut-off values from Castera et al. [14]; no/mild
fibrosis corresponds with stage F0/F1 (≤7.0 kPa), moderate fibrosis with F2/F3 (7.1–12.4 kPa), and
severe fibrosis with F4 (≥12.5 kPa). A liver biopsy using the Menghini technique [15] with a 1.8-mm
needle was carried out in 92 patients. The staging was performed according to the classification of
Desmet et al. [16]. Overall, 38 cases were diagnosed with liver cirrhosis (fibrosis stage F4) according to
the biopsy results.
The AST to platelet ratio index (APRI) and Forns index for the assessment of liver fibrosis in
chronic HCV patients could only be determined in 144 and 138 patients respectively, due to missing
laboratory values for other patients.
Plasma concentration of VAP-1 was determined using an enzyme-linked immunoassay (ELISA)
from R&D Systems (Minneapolis, MN, USA). According to the manufacturer, the intra-assay
variation was 2.1%/1.5%/2.4%, while the inter-assay variation was 4.5%/4.8%/4.7% in three
independent experiments.
We measured the SSAO activity using an Amplex ® Red Monoamine Oxidase assay kit from
Invitrogen™ Molecular Probes™ (ThermoFisher Scientific, Waltham, MA, USA). SSAO activity was
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determined by a fluorometric detection of hydrogen peroxide produced by different amino oxidases,
including the semicarbazide-sensitive amino oxidase (SSAO, the enzymatic domain of VAP-1) after
adding benzylamine as a substrate. Each sample was measured with and without the specific SSAO
inhibitor semicarbazide and the specific activity was calculated by subtraction.
Statistical analysis was performed with SPSS 22.0 (IBM, Armonk, NY, USA). According to the
Kolmogorov–Smirnov test, the VAP-1 concentration and its activity were not normally distributed.
Hence, after log transformation, we used Mann–Whitney U test for the comparison of medians or
ANOVA followed by Bonferroni post hoc test for multiple comparisons. Nonparametric Spearman
correlation coefficient was used for non-normal data. Linear regression analysis was used to test
for independent associations and clusters were compared with the Kruskal–Wallis test. For the
determination of cut-off values and the calculation of the associated sensitivity and specificity, we used
receiver operating characteristic (ROC) curve analysis. We use boxplots to present the results, and the
dots represent the outliers. Results were considered significant at p < 0.05. The effect size is given by
the beta values.
3. Results
Table 1 summarizes the baseline patient characteristics. The study cohort involved 322 patients
(98 women and 224 men). The mean age was 49.7 (±12.1) years and the mean body mass index (BMI)
was 24.3 (±4.6) kg/m2. The liver stiffness values were not consistent with biopsy results in three
patients with liver biopsy-confirmed cirrhosis. Moreover, nine patients were above the general liver
stiffness cut-off value for cirrhosis (12.5 kPa), but were classified with stage F0–F3 fibrosis on the basis
of the biopsy results. However, in 87% of the cases, liver stiffness and biopsy results were concordant.
Overall, 106 patients had values higher than the cut-off for cirrhosis, whereas 216 patients had liver
stiffness values less than 12.5 kPa.
Table 1. Characteristics of the study cohort. The classification between no/mild, moderate and severe
fibrosis is based on liver stiffness as assessed by transient elastography (Fibroscan®). No/mild fibrosis
≤7.1 kPa; moderate fibrosis 7.1–12.4 kPa; severe fibrosis ≥12.5 kPa. The N, the average and the p values
for the differentiation between the fibrosis stages are given. Statistical analysis was performed with
ANOVA followed by the Bonferroni post-hoc test. Significance is given as * p < 0.05, ** p < 0.01, and


















Sex (1 = male, 2 = female) 322 1.34 1.28 1.26 1.00 0.515 1.00
Age (years) 322 46.90 50.92 52.74 0.113 <0.001 *** 0.574
Body mass index (BMI) in kg/m2 302 23.76 25.06 24.72 1.00 0.33 1.00
Liver stiffness (kPa) 322 5.26 9.05 29.81 <0.001 *** <0.001 *** <0.001 ***
Plasma VAP-1 (vascular adhesion
protein-1) concentration in ng/mL 322 421.01 495.15 662.96 0.002 ** <0.001 *** <0.001 ***
SSAO (semicarbazide-sensitive
amino oxidase) activity in
ng/mL/min)
317 24.49 28.18 34.86 0.148 <0.001 *** 0.312
APRI (AST to platelet ratio index) 144 0.21 0.33 1.05 0.013 * <0.001 *** <0.001 ***
Forns index 138 7.17 8.15 10.34 0.017 * <0.001 *** <0.001 ***
Platelet count (1000/µL) 308 226.19 201.70 134.65 0.154 <0.001 *** <0.001 ***
Cholesterol (mg/dL) 223 171.07 167.26 153.86 1.00 0.111 0.301
GGT (gamma-glutamytransferase)
in U/I 258 57.12 90.61 182.24 <0.001 *** <0.001 *** <0.001 ***
GPT (glutamate pyruvate
transaminase) in U/I 257 61.36 90.66 122.00 0.003 ** <0.001 *** 1.00
GOT (glutamic oxaloacetic
transaminase) in U/I 254 40.13 56.25 103.06 <0.001 *** <0.001 *** <0.001 ***
Bilirubin (mg/dL) 255 0.67 0.68 1.16 1.00 <0.001 *** <0.001 ***
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The patients with liver stiffness of ≥12.5 kPa, presumably having cirrhosis, had significantly
higher plasma VAP-1 concentrations as compared to the patients with liver stiffness values less than
12.4 kPa and without cirrhosis (no/mild and moderate fibrosis). Similarly, the SSAO activity in
these patients was significantly higher in comparison to patients with no/mild fibrosis (Table 1).
The glutamic oxaloacetic transaminase (GOT) and gamma-glutamytransferase (GGT) activities, as well
as bilirubin and thrombocytes, also differed significantly between patients with or without severe
fibrosis/cirrhosis. The APRI and Forns index significantly increased with liver stiffness (Table 1).
A comparison of VAP-1 concentrations and liver stiffness measurements (Figure 1A) shows a
strong linear correlation (r = 0.528 Spearman, p < 0.0001). Likewise, we compared VAP-1 concentrations
in patients classified in different fibrosis stages according to the biopsy results (Figure 1B). Here,
the VAP-1 concentration did not differ between the individual fibrosis stages. We attribute this, at least
in part, to the low number of biopsies in the individual groups (F0: N = 7, F2: N = 10, F3: N = 8).
Nevertheless, severe fibrosis, stage F4 indicating cirrhosis, showed highly significant difference from
mild (F1) fibrosis with p < 0.001 and significant difference from patients without fibrosis (F0) with a
p = 0.012.
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Figure 1. Vascular adhesion protein-1 (VAP-1) concentration and liver fibrosis. (A) VAP-1 concentration
and liver stiffness of all 322 patients. The cut-off value for liver cirrhosis was set at ≥12.5 kPa.
The line shows the trend of the VAP-1 concentration with increasing liver stiffness as assessed by
transient elastography; (B) VAP-1 concentration in different fibrosis stages as assessed by biopsy-based
histology. According to the Kruskal–Wallis test, there were no significant differences (p > 0.05) between
different biopsy-based fibrosis stages (F0 vs. F1, F2 or F3; F1 vs. F2 or F3 and F2 vs. F3). There were
significant differences between F0 vs. F4 (p = 0.012) and highly significant between F1 vs. F4 (p < 0.001).
Significance is shown as * p < 0.05, and *** p < 0.001.
The VAP-1 concentration also significantly correlated with glutamate pyruvate transaminase
(GPT), GOT, GOT/GPT ratio, GGT, cholesterol, bilirubin, albumin, platelets and age (Table 2).
The SSAO activity showed a lower but significant, correlation with these parameters.
Based on these results, we performed a linear regression analysis to test for independent predictors
for liver stiffness or fibrosis severity. Here, we included all the parameters which correlated with
VAP-1 concentration and SSAO activity in the regression analysis: These were namely; GOT, GPT, GGT,
cholesterol, bilirubin, platelets, age, weight, soluble fms-like tyrosine kinase-1 (sFlt1), high-sensitivity
troponin T (hsTnT), endoglin, pro brain natriuretic peptide (proBNP), APRI and Forns index. In this
analysis, VAP-1 concentration was the second strongest variable associated with liver stiffness after
GGT (VAP-1: beta = 0.197, T score = 2.451, significance p = 0.016). When including the recently
identified surrogate markers [17], the growth/differentiation factor 15 (GDF15), hepatocyte growth
factor (HGF) and placental growth factor (PLGF); in the model, VAP-1 was still the second strongest
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influencing variable (VAP-1: beta 0.185, T score = 2.218, p = 0.029, Table 3). The influence of SSAO
activity was less pronounced and was excluded in a stepwise procedure.
Table 2. Correlation analysis of VAP-1 concentration and semicarbazide-sensitive amino oxidase
(SSAO) activity with standard laboratory parameters. Spearman correlating coefficients (r) and p values
are shown. Significance is given as * p < 0.05, ** p < 0.01, and *** p < 0.001.
VAP-1 Concentration SSAO Activity
r p Value r p Value
Fibrosis stage 0.513 <0.001 *** 0.233 0.026 *
Age 0.294 <0.001 *** 0.114 0.043 *
Platelets −0.357 <0.001 *** −0.241 <0.001 ***
Albumin −0.460 <0.001 *** −0.261 <0.001 ***
GOT/GPT 0.636 <0.001 *** 0.530 0.002 **
GOT 0.460 <0.001 *** 0.279 <0.001 ***
GPT 0.255 <0.001 *** 0.209 <0.001 ***
GGT 0.327 <0.001 *** 0.156 0.013 *
Bilirubin 0.158 0.011 * 0.128 0.042 *
Cholesterol −0.171 0.010 * −0.143 0.035 *
Liver stiffness 0.528 <0.001 *** 0.347 <0.001 ***
APRI 0.474 <0.001 *** 0.211 0.011 *
Forns index 0.493 <0.001 *** 0.201 0.019 *
SSAO activity 0.535 <0.001 ***
Table 3. Linear regression analysis for independent predictors of liver stiffness. All variables correlating
with liver stiffness are included in the model. We determined the regression coefficients with standard
error, the beta coefficient and the statistics for co-linearity (tolerance and variance inflation factor (VIF)).
Statistical outcome: R = 0.855, R2 = 0.730, significance < 0.001 ***. Gamma-glutamytransferase (GGT)
was the strongest significant influencing variable for liver stiffness followed by VAP-1. Significance is








Constant −7.096 11.249 −0.631 0.530
VAP-1 conc. 0.012 0.006 0.185 2.218 0.029 * 0.414 2.414
SSAO activity 0.057 0.081 0.051 0.698 0.487 0.542 1.844
Age 0.080 0.125 0.066 0.637 0.526 0.270 3.697
Weight 0.062 0.056 0.065 1.103 0.273 0.822 1.217
APRI 1.362 2.529 0.084 0.539 0.591 0.118 8.465
Forns index −0.689 1.176 −0.104 −0.586 0.559 0.091 10.932
GGT 0.047 0.008 0.474 6.091 0.000 *** 0.473 2.115
GPT 0.001 0.026 0.006 0.058 0.954 0.256 3.905
GOT 0.009 0.059 0.029 0.148 0.882 0.075 13.335
Bilirubin −0.117 1.221 −0.007 −0.096 0.924 0.621 1.611
Cholesterol 0.008 0.018 0.027 0.432 0.667 0.743 1.345
Thrombocytes −0.028 0.023 −0.147 −1.222 0.225 0.198 5.048
Endoglin 0.270 0.110 0.181 2.467 0.015 * 0.536 1.867
HsTnT
(high-sensitivity troponin T) −0.039 0.043 −0.058 −0.924 0.358 0.741 1.350
sFlt1
(soluble fms-like tyrosine kinase-1) −0.017 0.060 −0.026 −0.275 0.784 0.308 3.243
PLGF
(placental growth factor) 0.185 0.149 0.126 1.241 0.218 0.279 3.586
GDF15
(growth/differentiation factor 15) 0.000 0.001 0.040 0.313 0.755 0.174 5.747
HGF
(hepatocyte growth factor) 0.001 0.001 0.140 1.454 0.149 0.308 3.251
proBNP
(pro brain natriuretic peptid) −0.001 0.000 −0.204 −1.873 0.064 * 0.243 4.118
We performed a ROC curve analysis to assess the cut-off value for VAP-1 in all 322 patients.
The analysis demonstrated that a cut-off of 541 ng/mL of VAP-1 predicted histologically confirmed
cirrhosis (in 92 patients) with a sensitivity of 74% and a specificity of 72% (Figure 2A). As for liver
J. Clin. Med. 2019, 8, 103 6 of 9
stiffness, a cut-off value ≥ 12.5 kPa predicted cirrhosis with a sensitivity of 75% and a specificity of
73% (Figure 2B).
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Figure 2. Receiver operating curve (A) to predict histologically confirmed cirrhosis (N = 92): sensitivity
74%; specificity 72%; area under the curve (AUC) 0.791, and (B) to predict liver stiffness cut-off for
cirrhosis (N = 322): sensitivity 75%; specificity 73%; AUC 0.799.
The biopsy results indicated significantly higher VAP-1 concentrations in patients with cirrhosis
(N = 92, no cirrhosis vs. cirrhosis with a p < 0.0001, Supplemental Figure S2). The classification of the
patients in mild (45%), moderate (22%) and severe fibrosis (33%) based on liver stiffness showed that the
VAP-1 concentration increased with fibrosis severity (Figure 3A). Both mild fibrosis in comparison to
moderate fibrosis and moderate fibrosis in comparison to severe fibrosis or cirrhosis was differentiated
according to the VAP-1 concentration (p = 0.003 and p < 0.001 respectively).
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Figure 3. VAP-1 concentration and SSAO activity in mild, moderate and severe fibrosis. The classification
is based on the liver stiffness. (A) VAP-I concentration. According to Kruskal–Wallis test, there
were significant differences between no/mild fibrosis vs. moderate fibrosis (p = 0.002 **), no/mild
fibrosis vs. severe fibrosis (p < 0.001 ***), moderate fibrosis vs. severe fibrosis (p < 0.001 ***) (B) SSAO
activity. According to Kruskal–Wallis test, there were significant differences between no/mild fibrosis
vs. moderate fibro is (p = 0.023 *), no/mild fibrosis vs. severe fibrosis (p < 0.001 ***), moderate fibrosis
vs. severe fi (p = 0.028 *).
In addition to its concentration, we measured the SSAO activity of VAP-1 in all patients. Although
we observed a strong corr lation with the VAP-1 co centration (Table 2) the SSAO activity of VAP-1
correlated only m derately with liver, APRI and Forns-index (Table 2) The SSAO activity of VAP-1
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significantly increased in advanced fibrosis stage (F4) in comparison to no/mild fibrosis with a p < 0.001
as shown in Figure 3B. Significant differences were also observed between no/mild and moderate
fibrosis (p = 0.023), as well as between moderate and severe fibrosis (p = 0.028).
In the investigated cohort, eight patients suffered from hepatocellular carcinoma (HCC).
The VAP-1 concentration in these patients was higher than the VAP-1 concentration in patients
with liver cirrhosis but without HCC, albeit this difference was not significant (p > 0.05).
4. Discussion
Varying concentrations of VAP-1 have been associated with CLDs indicating its possible role
in the pathophysiology of these diseases. In a recent study, VAP-1 concentration was significantly
higher in patients with NAFLD and NASH as compared to the patients with metabolic syndrome [5].
Based on these observations and others [18], VAP-1 was suggested as a potential therapeutic target in
NAFLD, and possibly in other CLDs.
In our study on 322 chronic HCV infection patients, we show that the VAP-1 concentration, as well
as the SSAO activity, were significantly elevated in patients with moderate or severe fibrosis especially
in the presence of cirrhosis. Fibrosis stages were determined from the liver stiffness as measured by
transient elastography.
A direct comparison of the VAP-1 values with the previously reported changes in NAFLD [5] is
not appropriate, yet our study indicates a stronger correlation of the VAP-1 concentration with GOT,
GPT, GGT, bilirubin, cholesterol, platelets and albumin as parameters of liver injury and liver function.
Furthermore, in our study, the VAP-1 concentration showed higher correlation coefficients for the
fibrosis stage in chronic hepatitis C infection than those reported for NAFLD and NASH. Notably, our
cohort included proportionally many more cirrhosis patients. The strong association between VAP-1
concentration and other laboratory parameters is likely due to our larger study cohort, which included
patients in different fibrosis stages. The previous study on NAFLD and NASH patients reported
increased VAP-1 concentration in fibrosis stage F ≥ 2 in comparison to F0/F1, whereas our study
shows a stronger correlation with progressive fibrosis. The VAP-1 concentration significantly increased
from mild to moderate and severe fibrosis. As the plasma VAP-1 concentration in CLDs is higher in
hepatic veins than in portal veins, and furthermore, the membrane-bound VAP-1 concentration is
elevated in hepatic stellate cells in increasing fibrosis [10], we assume that the affected liver parenchyma
is the main source of the elevated plasma VAP-1 in chronic hepatitis C infection as well.
According to previous studies, VAP-1 supports leukocyte transmigration in the inflamed tissue
and the deleterious effects of its SSAO activity lead to enhanced production of extracellular matrix
proteins and increased oxidative stress. This process contributes to progressive fibrosis that ultimately
leads to cirrhosis. Experimental studies showed a reduction of inflammation and fibrosis in VAP-1
deficient mice or in the presence of an SSAO inhibitor. We evaluated the SSAO activity in our cohort to
assess its correlation with progressive fibrosis. However, in our study, the increase in SSAO activity
was only moderate as compared to the increase in VAP-1 concentration. The SSAO activity correlated
less with the markers of liver damage and did not allow an estimation of the progression of fibrosis.
However, the difference between no/mild fibrosis vs. severe fibrosis/cirrhosis was highly significant.
Possibly, the SSAO activity may no longer play a significant role when moderate and advanced fibrosis
stages are reached.
In multivariate analysis, VAP-1 was an independent predictor of fibrosis stages and was the
second strongest predicting variable after GGT. Our group has previously shown the predictive
value of three serum markers, namely PLGF, HGF and GDF-15, for liver stiffness and fibrosis stages.
Even when these parameters were included into the regression analysis, VAP-1 remained the second
strongest independent predictor of fibrosis suggesting its major role in the disease progression.
The significantly increased VAP-1 levels in the presence of cirrhosis allowed us to define a cut-off
value for cirrhosis. For cirrhosis, we calculated a cut-off of 541 ng/mL of VAP-1 based on the biopsy
results of 92 patients and a cut-off from the liver stiffness of more than 12.5 kPa in all 322 patients.
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These showed nearly the same predictive value. Furthermore, the non-invasive classification of the
fibrosis progression into mild, moderate and severe fibrosis demonstrated that the VAP-1 concentration
is also clearly elevated with moderate fibrosis. Presumably, VAP-1 levels continuously increase with
sustained injury to the liver parenchyma. Thus, VAP-1 concentration may represent a non-invasive
biomarker for progressive fibrosis and cirrhosis. Of note, in our study, we not only had liver stiffness
measurements for all chronic HCV infection patients, but we also had liver biopsy results in more
than a quarter of the cases. Additionally, we compared VAP-1 concentration and SSAO activity in all
patients. On the other hand, we cannot exclude a selection bias, as not all participants of the original
cohort with other CLDs could be included in our study. However, VAP-1 concentration differs between
individual CLDs, thus further disease-specific studies are necessary. In future studies, more HCC
patients should also be included to assess an increase of VAP-1 concentrations in patients who develop
liver cancer.
5. Conclusions
To our knowledge, this is the first study on VAP-1 in chronic hepatitis C infection showing a direct
association between VAP-1 plasma concentration and fibrosis severity. VAP-1 concentration increased
with the severity of fibrosis and was significantly elevated in patients with cirrhosis. Although the
SSAO activity of VAP-1 increased, the differences among the individual stages of fibrosis severity were
only partly significant. Therefore, we conclude that VAP-1 concentration, rather than its SSAO activity,
may represent a tool for monitoring fibrogenesis in the follow-up of patients with CLDs.
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